Nintedanib for Castleman disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a medication called nintedanib, which may help shrink or control the growth of Castleman disease when surgery isn't possible. It is a pill taken by mouth, and the goal is to see if it can help people with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed diagnosis of unicentric Castleman disease (a rare, non-cancerous growth in lymph nodes) from a biopsy
- The disease cannot be fully removed with surgery, or you have chosen not to have surgery
- You are able to take medication by mouth
- If you could become pregnant or get someone pregnant, you agree to use highly effective birth control during treatment and for 3 months after
- You are covered by the French national health system (or are a beneficiary of such a system)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a worldwide registry that collects basic medical information from people diagnosed with Castleman disease. It helps researchers learn about real-world care and outcomes across different ages and care settings.
This trial is looking back at the medical records of people with a rare condition called Castleman's disease to see how well the drug Siltuximab worked for them in everyday hospital care, not in a research setting. The goal is to learn more about how safe and effective the drug can be for patients in real life.
This trial tests the drug ruxolitinib for people with idiopathic multicentric Castleman disease (iMCD) whose symptoms are not well controlled by standard anti-IL-6 therapy. Ruxolitinib is a pill taken by mouth that may help reduce inflammation and improve symptoms.
This trial tests a new medicine called VDJ001 for people with idiopathic multicentric Castleman disease (iMCD), a rare condition causing enlarged lymph nodes and symptoms like fever, fatigue, weight loss, and poor appetite. The goal is to see if VDJ001 can help control the disease and improve symptoms.
This trial tests a drug called daratumumab for people with certain HIV-related blood cancers (primary effusion lymphoma, plasmablastic lymphoma) or a related condition called multicentric Castleman disease that has come back or not improved after standard treatment. The drug targets a protein on cancer cells to help the immune system attack them. It might be a new option when standard chemotherapy isn't working or isn't suitable.
This study tests a drug called pacritinib for people with KSHV-associated multicentric Castleman disease (MCD) or KSHV-associated inflammatory cytokine syndrome (KICS). It aims to see if the drug can help control symptoms and inflammation caused by these conditions.
Hear when a new Castleman Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.